Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elexixis advances three drugs into phase II tests
The company intends to begin a phase II program on its anticancer compounds, with the working names XL999 and XL647, before the end of this year, with results
The company intends to begin a phase II program on its anticancer compounds, with the working names XL999 and XL647, before the end of this year, with results
Desilux, a low-potency topical steroid, is the first drug formulated in the company’s patented “emollient (soothing) foam delivery vehicle”. The company says that the foam does not feel
In a report published in Clinical Cancer Research, the researchers say that the “Stat5” protein in the nucleus of prostate cancer cells was a significant predictor of which
According to the company, the market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due
The new European approval for the drug allows it to be used as a first-line treatment for severe, active and progressive rheumatoid arthritis, and can be used in
This newly identified set of molecules is called microRNA (miRNA), a collection of hundreds of snippets of non-coding RNA – typically no more than 22 nucleotides in length
The researchers studying a protein called km23, a protein that helps to direct protein cell traffic, have found that at least 42 percent of ovarian cancer patient tumor
The study (KEEPS) will explore whether beginning hormone therapy in women during the menopausal transition (ages 42 to 58) protects against atherosclerosis, the major cause of heart attacks.
Relenza is only available in an inhaled form, raising concerns that this method of delivery might not be ideal in an emergency situation, and could lead to the
To obtain the drug, patients must now register with the program, named iPLEDGE, and also must comply with a number of key requirements that include completing an informed